ResMed (NYSE: RMD) is expected to report Q4 earnings on Aug. 1. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict ResMed's revenues will grow 10.8% and EPS will grow 14.8%.

The average estimate for revenue is $412.2 million. On the bottom line, the average EPS estimate is $0.62.

Revenue details
 Last quarter, ResMed reported revenue of $383.6 million. GAAP reported sales were 9.9% higher than the prior-year quarter's $349.1 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, non-GAAP EPS came in at $0.59. GAAP EPS of $0.58 for Q3 were 32% higher than the prior-year quarter's $0.44 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 62.4%, 210 basis points better than the prior-year quarter. Operating margin was 25.1%, 320 basis points better than the prior-year quarter. Net margin was 22.1%, 360 basis points better than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $1.51 billion. The average EPS estimate is $2.27.

Investor sentiment
 The stock has a three-star rating (out of five) at Motley Fool CAPS, with 193 members out of 209 rating the stock outperform, and 16 members rating it underperform. Among 68 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 64 give ResMed a green thumbs-up, and four give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on ResMed is outperform, with an average price target of $45.46.

Is ResMed the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.